# A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

> **NCT01774786** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 780 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** 5-Fluorouracil
- **DRUG:** Capecitabine
- **DRUG:** Cisplatin
- **DRUG:** Pertuzumab
- **DRUG:** Placebo
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT01774786
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-10
- **Primary completion:** 2016-12-09
- **Final completion:** 2019-12-31
- **Target enrollment:** 780 (ACTUAL)
- **Last updated:** 2020-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01774786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01774786, "A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01774786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*